imatinib has been researched along with hh-gv678 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, W; Wang, X; Xi, Q; Yang, M | 1 |
| Hao, RR; Huang, WH; Liang, MH; Pan, YL; Shen, ZR; Zeng, SX | 1 |
1 review(s) available for imatinib and hh-gv678
| Article | Year |
|---|---|
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
1 other study(ies) available for imatinib and hh-gv678
| Article | Year |
|---|---|
Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Protein Kinase Inhibitors | 2019 |